122 hasil
Menampilkan 1–20 · 0,32 detik · RSS
Annals of Urologic Oncology
ISSN 2617-7765 · Asian Medical Press Ltd.(H.K.) · 122 artikel di indeks
-
Artikel Jurnal
Targeting Cellular Senescence in Prostate Cancer: Molecular Landscape and Therapeutic Avenues
Prostate cancer is one of the major causes of cancer morbidity and mortality in men, especially at advanced stages where treatment fails. Despite the fact that the existing treatment options, such as androgen deprivation therapy, chemotherapy, radiotherapy, PARP inhibitors, and targeted agents, can…
-
Artikel Jurnal
Adenoid Cystic (Basal Cell) Carcinoma of the Prostate: A Rare Entity with Diagnostic Challenges and Therapeutic Uncertainty
Background Adenoid cystic carcinoma (ACC), also referred to as basal cell carcinoma (BCC) of the prostate— a term used synonymously in the literature to describe the same clinicopathological entity— is an exceedingly rare malignant neoplasm. Initially described in the salivary glands by Billroth in…
-
Artikel Jurnal
A Diagnostic Twist: Primary Bladder Adenocarcinoma Masquerading as an Ovarian Torsion: A Case Report on Unusual Cystic Presentation
Primary bladder adenocarcinoma (PBA) is a rare malignancy comprising of only 0.5–2% of all bladder cancers and typically presents with nonspecific urinary symptoms. Cystic presentation is extremely uncommon and can mimic other pelvic pathologies. We report a very rare case of PBA in a 40-year-old…
-
Artikel Jurnal
Incidentally Discovered Primary Renal Leiomyosarcoma in a Middle Aged Female Presenting with Symptoms of Incomplete Abortion: A Rare Case Report
Background Primary renal leiomyosarcoma (LMS) is an exceptionally rare malignant mesenchymal tumor, constituting
-
Artikel Jurnal
Synthetic Lethality in Prostate Cancer: Evaluating the Role of PARP Inhibitors in BRCA-Mutated mCRPC
Prostate cancer, a leading cause of cancer-related mortality in men, often progresses to metastatic castration-resistant prostate cancer (mCRPC) despite advances in treatment with androgen-receptor pathway inhibitors (ARPIs) and taxanes. Recent genomic studies have highlighted that alterations in…
-
Artikel Jurnal
Saliva-Based Polygenic Risk Scores and AI-Enhanced Imaging for Prostate Cancer Screening beyond PSA
Background Prostate-specific antigen (PSA) testing, long used for prostate cancer screening, is limited by poor specificity (~25%), leading to unnecessary biopsies in over 70% of cases and substantial healthcare costs. Methods This review synthesizes recent evidence (2023–2025) on emerging…
-
Artikel Jurnal
The Urological Subtleties of an Uncommon Encounter with Primary Mucinous Adenocarcinoma of the Urinary Bladder with Review of Literature
Primary mucinous adenocarcinoma (PMA) of the urinary bladder is a rare and aggressive neoplasm, accounting for 0.5-2% of bladder malignancies. We report a case of a 52-year-old male presenting with urinary obstructive symptoms and hematuria. Imaging revealed a bladder mass, and histopathology…
-
Artikel Jurnal
Metabolic Reprogramming in Kidney Cancer: Implications for Therapy
Kidney cancer, particularly clear cell renal cell carcinoma (ccRCC), has emerged as a paradigm for cancer metabolic reprogramming, exhibiting distinctive alterations that drive tumor progression and therapeutic resistance. This comprehensive review synthesizes current knowledge of the molecular…
-
Artikel Jurnal
The Concomitant Use of Angiotensin System Inhibitors Predicts Favorable Prognosis for Renal Cell Carcinoma Patients
Objective Previous data suggest that Angiotensin system inhibitors (ASIs) may exert antitumor effects; however, the findings remain controversial. Therefore, the present study was conducted to evaluate the association between concomitant use of ASIs and survival outcomes in patients with renal cell…
-
Artikel Jurnal
Using Artificial Intelligence to Advance Renal Cancer Diagnosis, Treatment, and Precision Medicine
Renal cancer (RC) ranks tenth among the most frequently diagnosed cancers and affects both men and women worldwide. This disease is a significant global health issue, highlighting the need for accurate and rapid diagnostic tools to guide treatment. Conventional pathological methods have drawbacks…
-
Artikel Jurnal
Evolving Therapeutic Paradigms in Bladder Cancer: the Impact of Immunotherapy and Antibody-Drug Conjugates
Bladder cancer is a significant global health challenge. Despite advances in surgery and platinum-based chemotherapy over the decades, limited improvements in clinical outcomes have been observed. However, recent years have witnessed the development of immune checkpoint inhibitors (ICIs) and…
-
Artikel Jurnal
Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer
Renal cell carcinoma, with clear cell renal carcinoma (ccRCC) being the dominant form, is recognized as a malignancy driven by abnormal metabolic processes, with extensive alterations in glucose, lipid, and amino acid pathways. The loss of the Von Hippel-Lindau (VHL) gene in nearly 90% of ccRCC…
-
Artikel Jurnal
Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer
Prostate cancer (Pca) is a significant malignancy affecting men's health, with its incidence steadily increasing worldwide in recent years. Among its various subtypes, castration-resistant prostate cancer (CRPC) holds particular importance due to its pivotal role in the progression and management…
-
Artikel Jurnal
A Potential Role of MicroRNA in the Renal Cancer and Its Tumor Microenvironment
Renal cell carcinoma (RCC) accounts for approximately 2.2% of all diagnosed cancers and 1.8% of cancer-related deaths. Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of RCC, accounting for approximately 70–80% of all cases. Despite significant advancements in therapeutic…
-
Artikel Jurnal
Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication
Renal cell carcinoma (RCC) is the common type of kidney cancer linked to alteration of lipid, glucose, and amino acid metabolism. Early stage RCC has prognosis with overall 5-year survival rate of 90%, and the RCC has unfavorable prognosis when the disease metastasizes. Loss of or carrying mutated…
-
Artikel Jurnal
Role of Hyperbaric Oxygen Therapy in Prostate Tumor Microenvironment and Cancer Stem Cell Niche
Hyperbaric oxygen therapy (HBOT), has gained attention in recent years as a potential adjunct to conventional cancer treatments, particularly in addressing tumor hypoxia which is extensively employed as a post-injury treatment, is the administration of >92% oxygen at 1.5- 3.0 ATA for 60-120…
-
Artikel Jurnal
Testicular Carcinoma: Molecular Pathogenesis, Diagnostic Advances, and Evolving Therapeutic Strategies
Testicular carcinoma is the most common solid tumor in young male patients. Despite a high rate of survival, current treatments come with significant long-term toxicities, highlighting the need for more precise diagnostics and therapies. The current review focuses on the molecular pathogenesis…
-
Artikel Jurnal
Evolving Precision Therapy Paradigm against Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine cancer type, posing significant clinical challenges due to its diverse molecular features and poor treatment outcomes. At the molecular level, abnormalities in pathways, such as IGF2 signaling, Wnt/β-catenin activation…
-
Artikel Jurnal
Non-Histone Chromatin Protein Dysregulation: The Oncogenic Role of HMGB1 and Its Redox States in ccRCC Inflammation and Genome Instability
High Mobility Group Box 1 (HMGB1) is non-histone chromatin protein that plays important roles in maintaining nuclear architecture, transcriptional modulation, DNA replication, chromatin restructuring and DNA damage repair. In addition to its classical nuclear roles, HMGB1 predominantly functions as…
-
Artikel Jurnal
Prostate-Specific Membrane Antigen (PSMA) PET-CT: Revolutionizing Staging, Restaging, and Treatment Response Assessment
Prostate-specific membrane antigen (PSMA) positron emission tomography–computed tomography (PET-CT), has become the benchmark imaging tool in the management of prostate cancer, due to its unparalleled precision in staging, restaging and assessing of treatment response. Traditional imaging…